A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants With Advanced Breast Cancer
This study is testing a new experimental medicine called MEN2312, both by itself and combined with another medication called elacestrant. Researchers want to see if this approach is safe and helpful for adults with advanced breast cancer.
You might be able to join if you have advanced breast cancer with specific genetic changes that has grown despite previous treatments like hormone therapy and CDK4/6 inhibitors. However, you cannot join if the cancer has spread to your brain or spinal cord, or if you have severe organ symptoms from the cancer.
Participants will receive the study drug MEN2312, and some may also receive elacestrant. Your health and any side effects will be closely monitored by the study team throughout the process.
This study is currently recruiting participants at locations in Springdale, Arkansas, as well as Duarte and La Jolla, California.
- 1Testing a new experimental drug named MEN2312 for advanced breast cancer
- 2Open to patients whose cancer has specific genetic changes and progressed on standard treatments
- 3Currently recruiting patients at select locations in Arkansas and California
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.